BioInvent International AB (publ) (BINV.ST)
- ACCESSWIRE
BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 at PAGE 2024
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster ...
- ACCESSWIRE
BioInvent Gains Patent for BI-1808 in China
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
- ACCESSWIRE
BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's Lead Candidates BI-1808 and BI-1206
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company ...
